Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

Jin Wang, Shanbo Ma, Long Li, Yuhan Chen, Qian Yang, Feiyan Wang, Mei‐Ling Zheng, Shan Miao, Xiaopeng ShiFrontiers in Pharmacology 2022 · DOI

Abstract

Patients with breast cancer (BRCA) are particularly susceptible to SARS-CoV-2 infection due to compromised immunity. This study investigates the therapeutic potential of Diosmetin, a natural flavonoid, using a bioinformatics and network pharmacology approach. We analyzed the binding capacity, biological functions, and core genetic targets of Diosmetin in the context of BRCA and COVID-19. A prognostic model was developed to identify core genes and their correlation with patient survival and clinicopathological features. Molecular docking confirmed strong binding between Diosmetin and key proteins like TMPRSS2 and EGFR. Functional enrichment analyses (GO and KEGG) indicated that Diosmetin may inhibit inflammation and modulate the immune microenvironment. These findings provide a molecular basis for Diosmetin as a potential dual-action therapy for BRCA patients infected with SARS-CoV-2.

Introduction

The intersection of breast cancer and COVID-19 presents a significant clinical challenge. BRCA patients often face heightened vulnerability to severe SARS-CoV-2 infection due to immunosuppression from both the malignancy and systemic treatments like chemotherapy. While therapies exist for each condition independently, there is a critical need for agents that can address the shared molecular pathways of both diseases.

Diosmetin, a flavonoid found in citrus fruits and legumes, is known for its anti-inflammatory and anti-cancer properties. This study aims to map the "interactome" between Diosmetin, BRCA, and COVID-19 to determine if it can serve as an effective therapeutic intervention.

Methodology

The researchers employed a comprehensive computational pipeline to explore the drug's mechanism:

  1. Data Acquisition: Transcriptome data for BRCA was sourced from The Cancer Genome Atlas (TCGA), while COVID-19 associated genes were identified via GeneCards and OMIM.
  2. Differential Expression and Intersection: Genes significantly altered in BRCA were intersected with COVID-19 genes to find common targets.
  3. Network Pharmacology: Protein-Protein Interaction (PPI) networks were constructed using STRING and Cytoscape to identify high-connectivity "hub" genes.
  4. Functional Enrichment: Gene Ontology (GO) and KEGG pathway analyses were performed to identify the biological processes and signaling pathways targeted by Diosmetin.
  5. Prognostic Modeling: Univariate and Multivariate Cox regression analyses were used to identify genes with significant impact on patient survival.
  6. Molecular Docking: AutoDock Vina was used to simulate the physical binding of Diosmetin to target proteins like TMPRSS2 and EGFR.
Enrichment analysis and network construction showing the biological pathways and protein interactions targeted by Diosmetin.

Results and Discussion

Shared Genetic Landscape and Hub Genes

The analysis identified 337 genes shared between BRCA and COVID-19, highlighting a substantial overlap in biological machinery, particularly concerning cell cycle regulation and inflammatory responses. Within this network, five core prognostic genes—RACGAP1, TCF7L2, IRF7, DMD, and JUN—were found to be significant predictors of patient survival.

Multi-Target Mechanism and Binding Affinity

Diosmetin demonstrates a multi-target pharmacological profile. It interacts with a hub of 10 core proteins, including EGFR (involved in cancer growth), AKT1 (cell survival), and GSK3B (inflammation). Molecular docking revealed high binding stability, with energies of -9.3 kcal/mol for EGFR and -9.4 kcal/mol for AKT1. Notably, Diosmetin showed strong affinity for TMPRSS2, the protease SARS-CoV-2 requires for cell entry, suggesting a potential role in reducing viral load.

Survival Stratification and Immune Modulation

The prognostic model successfully stratified patients into high-risk and low-risk groups. The low-risk group exhibited significantly better survival outcomes, validating the clinical relevance of the identified core genes.

Correlation between core target genes and patient survival, including heatmap of gene expression and survival probability plots.

Enrichment analysis further suggested that Diosmetin modulates the immune system by inhibiting Th17 cell differentiation and the NF-kappa B signaling pathway. These pathways are central to the "cytokine storm," the hyper-inflammatory state responsible for severe COVID-19 complications.

Conclusion

This study provides the first bioinformatics-based evidence for the molecular functions of Diosmetin in BRCA patients with COVID-19. By targeting both viral entry mechanisms and oncogenic/inflammatory pathways, Diosmetin emerges as a promising candidate for further drug development. However, as this research is entirely in silico, experimental validation in cell cultures and animal models is essential to confirm these predicted interactions and assess clinical safety and efficacy.

Summary updated

Abstract

Patients with breast cancer are prone to SARS-CoV-2 infection [the causative virus of coronavirus disease (COVID-19)] due to their lack of immunity. In the current study, we examined the mechanism of action of Diosmetin, a flavonoid with anti-inflammatory properties, in patients with BRCA infected with SARS-CoV-2.We used bioinformatics technology to analyze the binding ability, biological function, and other biological characteristics of Diosmetin <i>in vivo</i> and examine the core target and potential mechanism of action of Diosmetin in patients with patients with breast cancer infected with SARS-CoV-2. A prognostic model of SARS-COV-2-infected breast cancer patients was constructed, and the core genes were screened out, revealing the correlation between these core genes and clinicopathological characteristics, survival rate, and high-risk and low-risk populations. The docking results revealed that Diosmetin binds well to the core genes of patients with breast cancer with COVID-19. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses suggested that Diosmetin inhibited inflammation, enhanced immune function, and regulated the cellular microenvironment in patients with BRCA/COVID-19. For the first time, we reveal the molecular functions and potential targets of Diosmetin in patients with breast cancer infected with SARS-CoV-2, improving the reliability of the new drug and laying the foundation for further research and development.
BibTeX
@inproceedings{wang2022investigation,
  author = {Jin Wang and Shanbo Ma and Long Li and Yuhan Chen and Qian Yang and Feiyan Wang and Mei‐Ling Zheng and Shan Miao and Xiaopeng Shi},
  title = {{Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.983821},
}
Figure